GenSight's GS010 misses in second Phase III for Leber hereditary optic neuropathy
By Chris Lieu | Feb 15, 2019 | 8:03 PM GMT
GenSight Biologics S.A. (Euronext:SIGHT) reported that GS010 (rAAV2/2-ND4) missed the primary endpoint of improving visual acuity in the Phase III RESCUE trial to treat Leber hereditary optic neuropathy (LHON).
On the 39-patient trial's
Read the full 325 word article
User Sign In
This article may not be distributed to non-subscribers
PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD